Methods and compositions for regenerating articular cartilage
Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.
1. A method of treating a partial thickness defect or area of reduced volume of articular cartilage in the joint of an individual comprising the steps:
a. administering to the partial thickness defect or area of reduced volume of articular cartilage an effective amount of an infiltration suppressor agent that suppresses or inhibits infiltration of synoviocytes, fibroblasts, or subchondral bone marrow cells into the defect or area, wherein the infiltration suppressor agent is a corticoid steroid or a combination of a corticoid steroid and a cartilage derived morphogenetic protein (CDMP), and
b. administering to the partial thickness defect or area of reduced volume of articular cartilage an effective amount of a columnar growth promoting agent that promotes columnar growth of articular chondrocytes in the defect or area, wherein the columnar growth promoting agent is selected from the group consisting of a bone morphogenetic protein (BMP), an insulin-like growth factor (IGF), a fibroblast growth factor (FGF), and combinations thereof.
2. The method according to claim 1 , wherein the corticoid steroid is dexamethasone.
3. The method according to claim 1 , wherein the CDMP is CDMP-1 or CDMP-2.
4. The method according to claim 1 , wherein the infiltration suppressor agent is a combination of dexamethasone and CDMP-2.
5. The method according to claim 1 , wherein the BMP is selected from the group consisting of BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, heterodimers thereof, and combinations thereof.
6. The method according to claim 1 , wherein the FGF is FGF-8.
7. The method according to claim 1 , wherein the IGF is IGF-1.
8. The method according to claim 1 , wherein the columnar growth promoting agent is a combination of a BMP and an FGF.
9. The method according to claim 8 , wherein the FGF is FGF-8.
10. The method according to claim 1 , wherein the infiltration suppressor agent and the columnar growth promoting agent are administered to the defect site or area of reduced volume of articular cartilage separately.
11. The method according to claim 1 , wherein steps a. and b. are performed simultaneously.
12. The method according to claim 1 , wherein the infiltration suppressor agent is administered to the defect site or area of reduced volume of articular cartilage and thereafter the infiltration suppressor agent is mixed with the columnar growth promoting agent and that mixture is then administered to the defect site or area of reduced volume of cartilage.
13. The method according to claim 1 , wherein the defect is surgically modified to provide a well defined defect site or area of reduced volume of articular cartilage prior to administering the infiltration suppressor agent or the columnar growth promoting agent.
14. A method of treating a partial thickness defect or area of reduced volume of articular cartilage in the joint of an individual comprising the steps:
a. administering to the partial thickness defect or area of reduced volume of articular cartilage an effective amount of an infiltration suppressor agent that suppresses or inhibits infiltration of synoviocytes, fibroblasts, or subchondral bone marrow cells into the defect or area, wherein the infiltration suppressor agent is a corticoid steroid or a combination of a corticoid steroid and a cartilage derived morphogenetic protein (CDMP), and
b. administering to the partial thickness defect or area of reduced volume of articular cartilage an effective amount of a columnar growth promoting agent that promotes columnar growth of articular chondrocytes in the defect or area, wherein the columnar growth promoting agent is a bone morphogenetic protein (BMP) selected from the group consisting of BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, heterodimers thereof, and combinations thereof.
15. The method according to claim 14 , wherein the corticoid steroid is dexamethasone.
16. The method according to claim 14 , wherein the CDMP is CDMP-1 or CDMP-2.
17. The method according to claim 14 , wherein the infiltration suppressor agent is a combination of dexamethasone and CDMP-2.